Screening for Roche Alzheimer's studies
Part of Brain & nervous system, Mental health clinical trials.
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to join a longer Alzheimer's study if you qualify
- You can get information about possibly joining another Roche Alzheimer's study
- You do not need help with basic daily tasks (like eating or dressing) because of memory loss
- You do not have another major brain condition (like Parkinson's or a stroke) that affects thinking
- Your hearing and vision are good enough to do thinking tests (glasses and hearing aids are okay)
- No serious medical problems that make a study unsafe for you
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.
This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
This trial is a brief survey to see if you might qualify for future neurology research studies. It helps researchers understand your health and find the right study for you.
This study screens people aged 60–80 for early signs of Alzheimer's disease in a community setting. Researchers will ask you questions and may perform brain imaging to understand who might benefit from early detection and treatment.
This study tests an investigational drug, ARO-MAPT-SC, which targets a protein involved in Alzheimer's disease. It is for people with early Alzheimer's to see if the drug is safe and can slow the disease.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.